Clinical Program Progress
Avacta's lead program, faridoxorubicin (FAP-Dox or AVA6000), is advancing with promising preliminary data in salivary gland cancers. The company also anticipates dosing the first patient with FAP-exatecan in Q1 2026.
Encouraging Preclinical Data
Updated preclinical data for FAP-exatecan shows durable complete responses in animal models, indicating potential efficacy and durability of the response.
Financial Management
Avacta maintains a cash runway into Q1 2026. Recent financial activities include renegotiation of the Heights Convertible Bond and raising GBP 6.5 million to fund bond payments.
Strategic Collaborations
The Tempus collaboration has confirmed the market opportunity for Avacta's pre|CISION medicines, showing FAP expression in 90% of patients with solid tumors.